Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Part A only: People who have been diagnosed with non-small cell lung cancer or certain other advanced cancers that have a specific gene change (ALK or ROS1 gene fusion), confirmed by lab testing. Any gender may be eligible for this part.
• Part B only: Women who have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by lab testing.
• People who have at least one tumor that can be measured on a scan.
• People who are generally well enough to carry out normal daily activities with little or no difficulty (confirm with trial site regarding the specific fitness score required).
• People who have a life expectancy of at least 3 months.
• People whose side effects from any previous cancer treatment have mostly resolved to a mild level or better.
• People who have adequate bone marrow, liver, kidney, and blood clotting function.
• Women who are not pregnant and not breastfeeding at the time of joining.
• People who are willing and able to understand and sign a consent form for the study.
• People who are able to provide a tumor tissue sample (either recently collected or previously stored) before starting treatment.

Who may not be able to join:

• People who have had major surgery, a significant injury, or a diagnostic biopsy recently before starting the trial (within specific timeframes — confirm with trial site).
• People who have recently received systemic cancer treatments, including other experimental drugs (confirm with trial site regarding the required waiting period).
• People who have had radiotherapy within 14 days before starting the trial.
• People who have previously been treated with a type of drug called a FAK inhibitor.
• People who have had a different type of cancer (other than ovarian cancer, for Part B participants) within the past 3 years before starting the trial.
• People who have active cancer spread to the brain or spinal fluid (known as CNS metastases or cancerous meningitis).
• People who have had a significant heart or stroke-related event within the past 6 months.
• People who have fluid build-up around the lungs, heart, or abdomen that requires or has recently required draining.
• People who have difficulty absorbing nutrients from food, or who are unable to swallow and take medication by mouth.
• People who have a severe gastrointestinal (digestive system) condition.
• People who have a serious or uncontrolled illness, or a chronic active infection.
• People who have a known allergy to the trial drugs (APG-2449 or PLD) or any of their ingredients.
• People who have previously received high cumulative doses of a certain class of chemotherapy drugs called anthracyclines (confirm with trial site for the specific dose threshold).
• People who are currently taking certain medications that interact with specific liver enzymes or drug transport systems in the body (confirm with trial site for the specific medications involved).
• People who the trial investigator believes should not participate for other medical or safety reasons.

Important: Always verify eligibility with the trial site directly before applying.